The preservation of β-keratin and pigment bodies in the fossil

Chinese and American scholars completed an article entitled "Early Cretaceous birds - the beginning of the Confucius bird feather keratin and molecular evidence of pigment body and published the paper on November 22 online in the Proceedings of the National Academy of Sciences, which also has other studies on recombinant horse proteins.

Dr. Pan Yanhong at Nanjing institute of geological paleontology, Chinese academy of sciences, Academician Zhou Zhonghe at Institute of Palaeontology and Paleoanthropology, Chinese Academy of Sciences, Professor Zheng Xiaoting from Linyi University, Shandong Province, China Prof. Shi Weicai from North Carolina State University, USA and his team conducted detailed Ultrastructure and biochemical analysis on the plumage of the first Confucius fossil specimen in the Shandong Tianyu Nature museum, confirming the preservation of β-keratin and pigment bodies in the fossil of 130 million years ago for the first time.

Current birds have colorful colors, which mainly depends on the feathers with the pigment body and feather internal structure. Feather pigment particles can be formed with the feathers into the different parts of the feathers, and thus the internal structure and other factors with the feathers can determine the different colors of the feathers.

However, the previous analysis of fossil feather pigments failed to accurately complete pigmentation of the signal in situ calibration to the pigment body. In this paper, a variety of chemical and molecular techniques were used to analyze chemical signals, including the immunoelectron microscopy (SEM) and ultra-high-resolution elemental energy spectroscopy (EHR), which were applied to fossil analysis for the first time. Their results not only confirmed the preservation of β-keratin in the fossils of 130 million years ago, but also confirmed that the micro-structure of feather fossils is wrapped by β-keratin, which are indeed the chromosomes of feathers. This work has advanced the age of β-keratin preservation for at least 50 million years, which is of great significance to better understand the soft tissue structure, the preservation of fossil molecules and the evolution of feather ultrastructure in ancient fossils. Flarebio provides you with superior recombinant proteins including recombinant Cdh11.

A protein that plays an important role in the accumulation of LDL cholesterol

The team led by Yale University has identified a protein that plays an important role in the accumulation of LDL cholesterol in blood vessels. The research was conducted using recombinant rat proteins. "This finding could lead to a treatment strategy that blocks LDL accumulation, which can help to prevent or slow the arterial blockage that causes heart disease," the researchers said. The study was published in the November 21 issue of Nature Communications.

When certain proteins (called lipoproteins) in the body bind to fat in the blood and transport the fat to the cells, the animals' blood vessels are blocked by fat and cholesterol. Scientists at first thought that LDL receptor molecules are responsible for intracellular LDL transport. However, in view of the fact that some individuals lack LDL receptors still have high levels of LDL, so questions remain about the mechanism.

To identify the mechanism, the team screened more than 18,000 genes (from the inner layers of human blood vessels) from the endothelium. They examined the genes involved in the process of LDL transfer into endothelial cells. The researchers found that the protein called ALK1 contributes to the pathway of LDL entry into the cell. "We have shown that ALK1 binds directly to LDL," said senior author William Cessa and professor of pharmacology Alfred Gilman. The team also identified the "LDL-ALK1 pathway" that helps LDL transit from the bloodstream to the tissues.

"The role of ALK1 in LDL accumulation has not been previously known, and the discovery of ALK1 as an LDL-binding protein suggests that it may initiate early stages of atherosclerosis. If we can find a small molecule or antibody that prevents ALK1 approach, then it can be used in conjunction with lipid-lowering strategies."

Current lipid-lowering strategies include statins, and it targets LDL cholesterol levels in the blood. "Therapeutic agents that block ALK1 will be a unique strategy to reduce the burden of atherosclerosis and have synergistic effects with lipid-lowering therapies," Sessa said. Heart disease caused by vascular damage is the leading cause of death worldwide. Flarebio provides you with good-quality recombinant proteins like recombinant Cdh26 at good prices.

Overweight can lead to abnormal blood flow, resulting in multiple myeloma

A new study from the University of Washington's St. Louis School of Medicine shows that overweight can lead to abnormal blood flow and may lead to multiple myeloma. We know that overweight or obesity increases the risk of multiple myeloma, a plasma cell tumor that occurs in the blood and bone marrow, and that the disease occurs more often after the age of 60. Before the occurrence of multiple myeloma, patients often appear first known as MGUS blood abnormalities. This anomaly refers to that the plasma cells will produce a number of antibody proteins, and this pre-cancerous lesion generally shows no symptoms, so it is difficult to be diagnosed.

"Our study using recombinant human proteins found that obesity can be a risk factor for predicting multiple myeloma," said Dr. Su-Hsin Chang of the University of Washington. "If a patient is diagnosed with MGUS, normal body weight is likely to be a preventable development method of multiple myeloma."

The researchers analyzed data from 7,878 patients (mainly males) who were diagnosed with MGUS between October 1999 and December 2009, and these data were obtained from the American Legionnaire database. Among these subjects, 39.8% were overweight and 33.8% were obese. The researchers followed the group to see if they eventually developed multiple myeloma. Finally, the researchers found that 4.6% of overweight patients (the average follow-up time of about 5.75 years) and 4.3% of obese patients (average follow-up time of about 5.9 years) eventually developed into multiple myeloma, and normal weight patients were only 3.5 %. For multiple myeloma, the results were statistically different. Overweight MGUS patients and obese MGUS patients were 55% and 98% more than normal-weight patients to be likely to develop multiple myeloma.

MGUS patients have elevated levels of antibody M (IgM), while about 3% of people who were more than 50 would show IgM rise, so MGUS is difficult to diagnose and there is no very effective treatment. Multiple myeloma is the third largest blood tumor. According to the American Cancer Society, in 2016, it is expected to have 30330 new patients, and about 12650 patients will die of multiple myeloma.

Dr. Su-Hsin Chang saidm, "According to our findings, overweight and obesity are risk factors for MGUS development into multiple myeloma, and our overweight and obesity are human intervention. We hope that our research results will provide a new strategy for the treatment of our disease. Moreover, we will further study the mechanism of obesity in promoting the development of MGUS to multiple myeloma." Flarebio provides you with good-quality recombinant CDH2 at great prices.

APOL1 gene can induce kidney disease

According to an article published in the November 18 issue of the American Journal of Nephrology, the National Institutes of Health System for Children has discovered a gene, APOL1, which induces kidney disease. The new form of the mutated APOL1 gene increases the risk of chronic kidney disease among people of African descent. Using a powerful genetic approach and recombinant horse proteins, national researcher of children was able to mimic APOL1 in Drosophila renal cell pathology. It opens the door to identifying other proteins that interact with APOL1, which is an important first step in identifying kidney disease that is currently drug-free.

The advantages of Drosophila in biomedical research include its rapid generation time and unparalleled ability to explore the basic biological processes of human underlying diseases through rich, complex genetic tools. People of African descent usually inherit APOL1 mutant genes to protect Africans from sleeping sickness in Africa, but this gene increases the odds of developing certain types of kidney disease by 17 to 30 times or more. Individuals are at higher risk of being infected with human immunodeficiency Viruses (HIV). Drosophila kidney cells, called kidney cells, accurately mimic the pathological features of human kidney cells in APOL1-associated kidney disease.

"Kidney cells have striking structural and functional similarities to mammalian podocytes and proximal tubule cells," says Zhe Han, an advanced Drosophila expert and associate professor of cancer and immunology at the Center for Cancer and Immunology. "This provides us with a simple kidney disease model system."

In a recent study, Han's team cloned the mutated APOL1 gene in cells from podocytes cultured in patients with HIV-associated nephropathy. They created transgenic Drosophila, similar to human APOL1 kidney cells, and observed that the initial transgene caused an increase in cellular functional activity. However, as the flies age, APOL1 leads to decreased cell function, increased cell size, abnormal vesicular acidification and accelerated cell death.

"The main function of kidney cells is to filter proteins, remove toxins from flowing blood, reabsorb protein components and chelate harmful toxins. Surprisingly, these cells begin to become more active and play a temporary role at a higher level. The cells become bigger and stronger, but they can't sustain this enhancement," said Han. "Cells die and cell hypertrophy is the way the human heart responds to stress overload after swelling to twice its normal size. We think that kidney cells may use the same coping mechanism."

The Children's Research Group is a multidisciplinary team of members from the Cancer and Immunology Research Center, the Center for Genetic Medicine Research and the Department of Nephrology. The group also characterizes flies phenotypes associated with APOL1 gene expression, which will facilitate the design and implementation of Drosophila gene screening methods to identify proteins that interact with APOL1 and contribute to disease mechanisms. Such proteins represent potential therapeutic targeting targets. Transplantation is currently the only option for patients with kidney disease associated with APOL1.

"It's just the beginning," Han said. "Now that we have an ideal preclinical model, we plan to start testing out-of-the-box therapeutic compounds, such as different kinase inhibitors, to determine if they block any steps leading to kidney cell disease." Flarebio offers recombinant proteins such as recombinant Itgb2 at competitive prices.

BAG5 protein can save the function of anti-oncoprotein p53

According to research using recombinant dog proteins, among the anti-oncoproteins found so far, p53 is undoubtedly one of the most well-known. It can achieve the curative effect of cancer by affecting cell division, apoptosis, metabolism and other important processes. In nearly half of the tumors, the gene TP53 which expresses this transcription factor show mutations, making p53 lose anti-cancer function. And some functional (GOF) mutations may even make p53 directly "renegade" and promote canceration and tumor resistance.

Mutant p53 is characterized by a greater stability, reflected by being more difficult to be mediated and degradated by ubiquitin ligase MDM2 and CHIP. Interestingly, this stability is limited to cancer cells but not in the normal cells. This allows the mutant p53 to accumulate in the tumor to a high level so as to play its role in promoting cancer. Then, what kind of difference do cancer cells have to make mutant p53 to accumulate at a high level?

Recently, the research team of Prof. Wenwei Hu and Prof. Zhaohui Feng of Rutgers, The State University of New Jersey found that BAG-2-related anti-apoptotic gene (BAG) family proteins BAG5 and BAG2 can prevent pan- Ligase and mutant p53 binding, thereby giving the latter cell-specific stability in the cancer. The results are published in the recent Nature Publishing Group publication Cell Discovery.

In a variety of human breast cancer and lung cancer cell lines and other systems, BAG5 of the five BAG domain can be R175H, R248W or R273H mutant p53 DNA binding domain (DBD) interaction, and BAG5 and wild type P53 between no affinity. At the same time, BAG2, another member of the BAG family, was found to have synergistic effects with BAG5 in enhancing mutant p53 stability. Concomitantly, when BAG5 was overexpressed, the level of mutant p53 was increased in cancer cells, and it decreased when BAG5 was knocked down.

By this interaction, BAG5 prevents MDM2 and CHIP from modifying ubiquitination of mutant p53, thereby ultimately inhibiting degradation of the p53 by the proteasome. Further experiments have shown that BAG5 is essential for the development of functional R248W mutations to play a role in carcinogenesis, including the ability to promote proliferation, proliferation, and drug resistance in cancer cells. It is worth noting that BAG5 is overexpressed in a variety of tumors including breast cancer, skin cancer, colorectal cancer, lung cancer and so on. And the higher the expression level, the worse the prognosis of patients.

BAG family proteins play an important regulatory role in cell division, differentiation and apoptosis, and their common BAG domains have molecular chaperone activity. In this study, BAG5 was found to have proto-oncogenic properties that enhance the ability of cancer cells to proliferate, diffuse and resist drug resistance by increasing the level of functional mutant p53 protein. Therefore, BAG5 has a potential as a therapeutic target for tumors expressing the aforementioned p53 protein. Flarebio provides good-quality recombinant proteins such as recombinant CDH2.

It's promising to treat Alzheimer's disease using gene therapy

Recently, a study from the Imperial College of Technology in London, England, has provided new possibilities for the treatment of Alzheimer's disease through recombinant human proteins. The researchers said their mice experiments showed that gene therapy may be successful in the treatment of Alzheimer's disease. The study was published in the Proceedings of the National Academy of Sciences.

Researcher Magdalena Sasite participating in the study of Imperial College London said that they used the modified lentiviral vector to inject a gene called PGC1-α into the memory region of the mouse brain. These mice just began to develop early symptoms of Alzheimer's disease. The results showed that this therapy prevented the accumulation of β-amyloid in the brain of mice, which is thought to cause brain cell death and was closely related to the pathogenesis of Alzheimer's disease.

The researchers said that after treatment with gene therapy for 4 months, few amyloid plaques of Alzheimer's disease existed in these mice brain. In the task-testing of memory, these treated mice behaved as well as healthy mice. In addition, their brain memory region also showed no loss of brain cells.

Genetic factors play an important role in the pathogenesis of Alzheimer's disease. Preston Estepp, director of Gerontology Research of "Personal Genome Project" of Harvard University School of Medicine and the author of the book Longevity of the Gene, said, "There are two most significant genes. They are apolipoprotein E (APOE) and amyloid precursor protein (APP)."

"More and more research evidence suggests that APOE is responsible for transporting iron into the brain. With the increase in iron accumulation, APP protein is also increasing to protect the brain cells and tissues. Then, the special cells that function as cleaners begin to work. A small portion of the APP will be cut off and discarded, and the abandoned part is β-amyloid protein, which is the culprit of formation of brain age spots. The enzymes which play cutting role play other roles in the cells, but the APP cut on the human body does not make any sense and may even cause collateral damage to the human body. With the accumulation of β-amyloid, functional brain cells will be killed and replaced," Estepp made the above explanation for the interaction of APOE and APP genes with iron.

Estepp suggested that we should pay more attention to the iron content of food. "For normal women, 18mg of iron can provide them with 100% of the daily intake. For other adults, the general daily 8mg of iron can be met," Estepp also said, "There are individual differences in iron uptake efficiency. In addition to the iron content of the food and the reasonable control of the intake, we can also monitor the key biomarkers for iron, including serum iron, serum ferritin, hemoglobin and so on.” Flarebio offers recombinant proteins of good quality such as recombinant Itgb2 at great prices.

There may be a short course of treatment for chronic hepatitis C

Recently, the study report of the annual meeting of the American Association for the Study of Liver Diseases states that RG-101, a candidate drug from Regulus Therapeutics in combination with direct-acting antiviral (DAA) therapy requires only four weeks of treatment to cure most of the hepatitis C patients, according to the research through recombinant rat proteins.

The treatment of hepatitis C in recent years has undergone great changes with the introduction of DAA therapy. This type of drug works directly on targets associated with hepatitis C virus replication. Compared with previous interferon-based therapies, it has better efficacy and fewer side effects. The advent of DAA drugs has made it possible to cure hepatitis C, but the current standard course of oral DAA is 8 to 24 weeks. The shortest course of treatment will not be less than 8 weeks.

RG-101 is an innovative injection therapy targeting microRNA-122 (miR-122, miR-122) developed by Regulus. MiR-122 is one of the most abundant miRs in the liver and plays an important role in the stability, replication and protein translation of hepatitis C virus in hepatocytes. The advantage of RG-101 is that it targets hepatitis C virus in a completely new pattern, and it is effective against all genotypes of hepatitis C virus against strains that are resistant to certain DAA drugs because of gene mutations. Therefore, its combination with DAA therapy may enhance the efficacy of hepatitis C virus and shorten the course of treatment.

The results reported in this scientific report came from a clinical phase 2 trial involving 79 patients with HCV. These patients received RG-101 injections on the first day and were divided into three groups, receiving four weeks of different types of oral DAA therapy approved by the FDA. The first group received ledipasvir / sofobuvivr treatment; the second group received simeprevir treatment; the third group received daclatasivr treatment. At the end of the 28-day course, the patient received another RG-101 injection on day 29.

The results showed that at the 12th week after the end of the treatment period, 100% of the patients in the first group, 96% in the second group and 92% of the third group had decreased to undetectable levels. At week 24 after the end of the treatment period, 100% of the patients in the first group, 80% of the patients in the second group and 89% of the patients in the third group were undetectable. And these combination therapies only have mild to moderate side effects, and no patients stopped treatment due to side effects.

"The focus of this research is to find shorter, better-effective and safer methods of treatment for hepatitis C," said one of the head of the clinical trial at the Hepatology Center of Buda in Budapest, Hungary. "Our results suggest that there may be a short course of treatment for chronic hepatitis C," Dr. Mihály Makara said. Flarebio provides you with good-quality recombinant proteins such as recombinant CDH15 at great prices.